Letter to the editor in response to the article "COVID-19 and diabetes: Can DPP4 inhibition play a role?"
- PMID: 32333972
- PMCID: PMC7177108
- DOI: 10.1016/j.diabres.2020.108163
Letter to the editor in response to the article "COVID-19 and diabetes: Can DPP4 inhibition play a role?"
Conflict of interest statement
Declaration of Competing Interest Author declare no conflict of interest.
Comment on
-
COVID-19 and diabetes: Can DPP4 inhibition play a role?Diabetes Res Clin Pract. 2020 Apr;162:108125. doi: 10.1016/j.diabres.2020.108125. Epub 2020 Mar 26. Diabetes Res Clin Pract. 2020. PMID: 32224164 Free PMC article. No abstract available.
References
-
- Rosenstock J., Aguilar-Salinas C., Klein E., Nepal S., List J., Chen R., CV181-011 Study Investigators Effect of saxagliptin monotherapy in treatment –naive patients with type 2 diabetes. Curr Med Res Opin. 2009;25(10):2401–2411. - PubMed
-
- Willemen M.J., Mantel-Teeuwisse A.K., Straus S.M., Meyboom R.H., Egberts T.C., Leufkens H.G. Use of dipeptidyl peptidase- 4 inhibitors and the reporting of infections: a disproportionaly analysis in the World Health Organization VigiBase. Diabetes Care. 2011;34(2):369–374. doi: 10.2337/dc10-1711.pmid:21270195. - DOI - PMC - PubMed
-
- Reinhold D., Biton A., Goihl A., Piper S., Lendeckel U., Faust J. Dual inhibition of dipeptidyl peptidase IV and aminopeptidase N suppresses inflammatory immune responses. Ann NY Acad Sci. 2007;1110:402–409. pmid:17911455. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
